Patients with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) have better responses to radiotherapy and higher overall survival rates than do patients with HPV-negative HNSCC, but the mechanisms underlying this phenomenon are unknown. p16 is used as a surrogate marker for HPV infection. Our goal was to examine the role of p16 in HPVrelated favorable treatment outcomes and to investigate the mechanisms by which p16 may regulate radiosensitivity. HNSCC cells and xenografts (HPV/p16-positive and -negative) were used. p16-overexpressing and small hairpin RNA-knockdown cells were generated, and the effect of p16 on radiosensitivity was determined by clonogenic cell survival and tumor growth delay assays. DNA double-strand breaks (DSBs) were assessed by immunofluorescence analysis of 53BP1 foci; DSB levels were determined by neutral comet assay; western blotting was used to evaluate protein changes; changes in protein half-life were tested with a cycloheximide assay; gene expression was examined by real-time polymerase chain reaction; and data from The Cancer Genome Atlas HNSCC project were analyzed. p16 overexpression led to downregulation of TRIP12, which in turn led to increased RNF168 levels, repressed DNA damage repair (DDR), increased 53BP1 foci and enhanced radioresponsiveness. Inhibition of TRIP12 expression further led to radiosensitization, and overexpression of TRIP12 was associated with poor survival in patients with HPVpositive HNSCC. These findings reveal that p16 participates in radiosensitization through influencing DDR and support the rationale of blocking TRIP12 to improve radiotherapy outcomes. 1,2 However, the mechanisms that underlie this phenomenon remain unknown. Clinically, p16 is used as a surrogate marker for HPV infection in HNSCC 2-4 because its expression is induced by HPV oncoprotein E7-related pRb inactivation and degradation. 5, 6 As a tumor suppressor, p16 has multiple biological functions, including cell cycle regulation, 5 cancer cell RT sensitization 7-9 and radiation-induced senescence. 10 Several studies have also reported that even in the absence of demonstrable HPV positivity, p16 positivity in patients with HNSCC is associated with improved survival.
INTRODUCTION
Patients with human papillomavirus (HPV)-positive stage III-IV head and neck squamous cell carcinoma (HNSCC) are known to have a more favorable prognosis after radiation therapy (RT), with or without chemotherapy, than do those with HPV-negative stage III-IV HNSCC (5-year overall survival rates 480% versus 40%). 1, 2 However, the mechanisms that underlie this phenomenon remain unknown. Clinically, p16 is used as a surrogate marker for HPV infection in HNSCC [2] [3] [4] because its expression is induced by HPV oncoprotein E7-related pRb inactivation and degradation. 5, 6 As a tumor suppressor, p16 has multiple biological functions, including cell cycle regulation, 5 cancer cell RT sensitization [7] [8] [9] and radiation-induced senescence. 10 Several studies have also reported that even in the absence of demonstrable HPV positivity, p16 positivity in patients with HNSCC is associated with improved survival. 11 However, the specific role of p16 overexpression in the context of the radiosensitivity of HPV-related HNSCC is not clear.
Recently, HPV-positive HNSCC cells were found to sustain more RT-induced DNA damage than HPV-negative cells. 9, 12 In cervical cancer, the distribution of 53BP1 nuclear foci was similar to that of punctate HPV signals and p16 expression. 13 In HPV-positive anal carcinoma, markedly enlarged 53BP1 foci were accompanied by dramatically increased RNF168 levels.
14 As a DNA damage repair (DDR) mediator and marker of unrepaired double-strand breaks (DSBs), [15] [16] [17] [18] [19] [20] 53BP1 is recruited to DNA damage sites and is regulated by RNF168. 21, 22 These observations suggest that HPV influences the effectiveness of RT through RNF168-53BP1 pathway-regulated DDR. As a DDR-related protein 14, [23] [24] [25] and a suppressor of RNF168, TRIP12 prevents excessive spreading of ubiquitinated chromatin at damaged chromosomes.
14 However, whether TRIP12 is involved in the favorable prognosis of HPV-positive HNSCC and its relationship with p16 in this process remain unknown. Because p16 mutation and methylation are widely present in cancer, [26] [27] [28] [29] [30] determining the role and mechanisms of p16 in radiation effects may reveal previously unidentified mediators of p16 and RT sensitization targets, leading to improved treatment outcomes.
In the current study, we used in vitro HNSCC cell models and in vivo HNSCC tumor xenografts to determine the role of p16 in HPV-positive RT sensitivity and explored the mechanisms of this effect. We found that p16 expression enhanced the RT responsiveness of HNSCC both in vitro and in vivo. In addition, p16 affected DDR via the TRIP12-RNF168-53BP1 cascade by suppressing TRIP12. We also verified that knockdown of TRIP12 rendered HNSCC cells sensitive to RT and delayed DDR. Finally, we found that in patients with HPV-positive head and neck cancer from the Cancer Genome Atlas, overexpression of TRIP12 was associated with poor outcome. The HPV-negative head and neck cancer cell lines, HN5, FaDu,  UMSCC-1 and Detroit 562, and the HPV-positive head and neck  cancer cell lines, UMSCC-47, 93-VuSCC-147T, UPCI-SCC-154 and  UPCI-SCC-090 , were used ( Figure 1a ). The treatment endpoint was clonogenic cell survival, which is the benchmark readout for in vitro RT sensitivity. 31 As previously observed, HPV-positive HNSCC cells were more radiosensitive than HPV-negative cells (Figure 1b) . To investigate the role of p16 in HPV-positive RT enhancement, we generated p16-overexpressing cells (HN5 and UMSCC-1) and p16-small hairpin RNA (shRNA) stable-knockdown cells (UMSCC-47 and UPCI-SCC-154). Compared with scramble control cells, p16 overexpression in HPV-negative HN5 or UMSCC-1 cells led to significant radiosensitization ( Figure 1c and Supplementary Figure S1a) , whereas knockdown of p16 rendered UMSCC-47 and UPCI-SCC-154 cells more radioresistant (Figure 1d and Supplementary Figure S1b) . To exclude the possibility that the Values shown are the means+SE of three independent experiments. (e) Xenografts generated by HN5 with p16-overexpressing cells. Growth delay during times of increasing diameter was significantly greater for HN5-p16 RT than for the Mock RT condition (unirradiated empty vector control) (P = 0.026). (f) Xenografts generated by UMSCC-47 cells with p16 knockdown. Growth delay was significantly greater (Po0.001) for Scramble RT than for sh-p16 RT at each diameter (9, 10, 11…mm) . Each data point in the radiation-induced tumor growth delay curve represents means of three to six mice; bars, SE.
RESULTS

p16 sensitizes HNSCC cells and tumor xenografts to RT
above effects are actually due to the function of p53, we tested the radiosensitivity changes of the HPV-positive UMSCC-47 cells following siRNA inhibition of p53. We found that following siRNA inhibition of p53, no significant change in radiosensitivity was observed in HPV-positive UMSCC-47 cells (Supplementary Figures  S1c and d ). This may due to the fact that p53 is inactivated by HPV E6 oncoprotein via several mechanisms. [32] [33] [34] Because p16 is necessary for the survival of some HPV-positive cervical carcinoma cells, 35 to exclude the possibility that loss of p16 may have led to slower growth of the HPV-positive HNSCC cells and subsequently to reduced sensitivity to RT, we assessed proliferation rates of HPV-positive UMSCC-47, UPCI-SCC-152 and UPCI-SCC-154 cells after ablation of p16 expression, using cell doubling time as an end point. Depletion of p16 expression had no influence on the proliferation rates of these HNSCC cell lines ( Supplementary  Figures S2a-c) . The HPV-positive cervical carcinoma cell line SiHa, whose proliferation has been previously shown to be affected by p16, 35 served as a positive control (Supplementary Figure S2d) . These observations indicated that p16 does not influence HNSCC cell radiosensitivity via cell growth rates.
We further validated our findings in mice bearing HN5 and UMSCC-47 tumor xenografts by using an RT tumor growth delay assay. 36 Clinically, HPV-positive tumors are more sensitive to RT than are HPV-negative tumors. Thus, in the current study, the HPV-positive UMSCC-47 tumors were irradiated for 5 days to a total dose of 20 Gy, and the HPV-negative HN5 tumors were irradiated for 7 days to a total dose of 28 Gy. In the HN5 tumors, forced expression of p16 had minimal effects on tumor growth in the absence of RT, but led to profound radiosensitization (Figure 1e ; red triangles vs blue triangles for HN5, P o0.001). Conversely, inhibition of p16 expression in UMSCC-47 tumors led to radioresistance (Figure 1f , red filled circle vs red blank circle for UMSCC-47, P = 0.002). Western blot analysis of tumor tissue lysates confirmed that p16 knockdown was retained throughout this tumor radiosensitivity study (Figure 1f) .
Together, these findings show that p16 expression in HNSCC cells can at least partially mediate favorable radiation response both in vitro and in tumor xenografts. p16 does not regulate RT response through the CDK4/CDK6 pathway One established function of p16 is the p16/cyclin D1/CDK4/pRb cell cycle regulatory cascade. 5 To determine whether p16 regulates RT response through this pathway, we used the CDK4/CDK6-specific inhibitor PD0332991, which is being evaluated in phase II clinical trials. 37 The PD0332991 dose that completely blocked CDK4/CDK6 activity was verified by western blot analysis (Supplementary Figure S3a) . PD0332991 did not affect RT sensitivity in scrambled or p16-overexpressed HN5 cells (Supplementary Figure S3b) , indicating that p16 does not regulate RT sensitivity through the p16/CDK4/cyclin D1/Rb pathway. p16 regulates RT response by influencing DDR The persistence of 53BP1 foci indicates unrepaired DSBs. [15] [16] [17] [18] [19] [20] In p16-overexpressing HPV-negative HN5 cells, but not in mock control cells, 53BP1 foci persisted for 24 h after 4 Gy γ-irradiation (Figures 2a and b) . Conversely, in scramble control HPV-positive UMSCC-47 cells, but not in p16-shRNA-knockdown cells, 53BP1 foci persisted for 24 h after 2 Gy γ-irradiation (Figures 2c and d) . These findings indicate that cells that express p16 are less able to repair DNA DSBs.
To confirm this result, we used a neutral comet assay to measure levels of DSBs 24 h after RT. p16-overexpressing HPVnegative HN5 cells exhibited a significant increase in the comet tail moment (percentage of DNA in the tail × tail length) p16 regulates the DDR-related TRIP12-RNF168-53BP1 pathway RNF168 is a positive regulator of 53BP1; 21, 22 in addition, in HPVpositive carcinoma, markedly enlarged 53BP1 foci have been shown to be accompanied by greatly increased RNF168 levels. 14 On the basis of these findings, we investigated whether p16 regulates DDR through this DDR-related RNF168-53BP1 pathway. We found that p16 expression was associated with RNF168 protein levels (Figures 3a and b, RNF168 antibody was verified in Supplementary Figure S4a) . Interestingly, TRIP12, a negative regulator of RNF168, 14 was inversely related to p16 expression (Figures 3a and b) . This inverse association with p16 was observed in additional head and neck cancer cell lines (Supplementary Figures S4b and c) and in UMSCC-47 xenograft tumors (Figure 3c ). These previously unidentified observations suggest that p16 modulates the TRIP12-RNF168-53BP1 pathway. In this loop, TRIP12 regulates RNF168, causing changes in 53BP1 foci. Thus, suppression of TRIP12's function may be a mechanism underlying p16-mediated RT sensitization.
p16 regulates TRIP12 at the post-translational level We found that the presence of p16 expression downregulated the expression of TRIP12 protein (Figures 3a-c, Supplementary  Figures S4b and c) . To determine the link between p16 and TRIP12 expression, we examined the influence of p16 on TRIP12 mRNA expression by using a polymerase chain reaction (PCR) assay and the protein half-life of TRIP12 by using a standard protein synthesis inhibitor cycloheximide assay. We found that p16 overexpression appeared to reduce the half- Silencing TRIP12 leads to enhanced radioresponsiveness through influencing DDR TRIP12 is known to influence the DDR.
14,23-25 However, its role in regulating RT sensitivity and the mechanisms of this effect on DDR have not been established. We assessed the influence of TRIP12 on RT response in HNSCC HN5 and FaDu cells. Knockdown of Trip12 sensitized HN5 and FaDu cells to RT, which recapitulated the effect of p16 overexpression (Figures 5a and b) . To confirm this result, we used a neutral comet assay to measure levels of DSBs at 24 h after RT. Trip12 knockdown in HN5 and FaDu cells led to significant increases in comet tail moment compared with the control scrambled cells (Figures 6a-d) . These findings indicate that cells with depleted TRIP12 expression have persistent DSBs and are less able to repair DNA DSBs. Because BRCA1 has an important role in DDR, 39 especially in homologous recombination (HR)-mediated repair, 40 we also examined BRCA foci after RT. We observed induction of BRCA1 foci at 1 and 5 h after 4 Gy γ-irradiation in HN5 and FaDu scramble control cells, and UMSCC-47 p16-knockdown cells, but the levels of these foci were reduced in the TRIP12 knockdown HN5 and FaDu cells, and UMSCC-47 scramble control cells (Figures 6e-h and Supplementary Figures S6a-c) , suggesting that TRIP12 regulates DDR through influencing HR-mediated repair.
TRIP12 expression is associated with poor treatment outcome To investigate the influence of TRIP12 on clinical treatment outcomes, we examined potential correlations between TRIP12 expression status and overall survival times of patients with HPVpositive HNSCC in The Cancer Genome Atlas database. In this pilot TRIP12 mediates p16 radiosensitization L Wang et al study, outcomes were poorer for 18 patients with high-TRIP12-expressing tumors than for another 18 patients with low-TRIP12-expressing tumors (Figure 7 ), indicating that the radioresistance conferred by TRIP12 observed in vitro may be associated with poor outcome in patients with HNSCC.
DISCUSSION
In our study, p16 overexpression sensitized HPV-negative HN5 cells and tumor xenografts to radiation. Moreover, even in the presence of HPV, inhibition of p16 in UMSCC-47 cells and tumor xenografts led to radioresistance. Our in vitro findings are consistent with a recently reported in vitro study 9 and are validated in our tumor xenograft experiments. On the basis of these results, we conclude that p16 has a key role in HPV-related RT enhancement.
The tumor suppressor p16 has multiple biological functions and has been extensively studied. Even though it has been shown to lead to radiosensitization in several cell lines, 7-9 its role in regulating radiosensitivity, particularly in the context of HPVpositive HNSCC, had not been elucidated, particularly in the context of DDR regulation. In the current study, we found that p16 enhanced the radiosensitivity of HNSCC by influencing DDR.
As an important DDR mediator and marker of unrepaired DSBs, [15] [16] [17] [18] [19] [20] 53BP1 is recruited to DNA damage sites and regulated by RNF168. 21, 22 In HPV-positive cervical cancer, the distribution of 53BP1 foci is similar to that of p16 overexpression, 12 and in HPVpositive anal carcinoma, markedly enlarged 53BP1 foci are accompanied by drastically increased RNF168 levels; 13 however, the direct link between p16 and 53BP1-RNF168 was unclear. In the current study, we found that p16 overexpression not only caused persistence of 53BP1 foci 24 h after RT but the protein levels of RNF168 were also modulated in a similar fashion. The converse was true in cells with inhibited p16. RNF168 is a histone E3 ubiquitin ligase with important positive roles in the DSB repair process, including avoiding collisions between transcription and repair intermediates, 41 facilitating fusion of uncapped telomeres, 42 and forming G1 nuclear bodies. 43, 44 However, RNF168 can amplify ubiquitin conjugates, generated by its own activity, that progressively spread away from the DSBs to undamaged chromatin and lead to uncontrolled amplification of chromatin ubiquitylation. 21, 45, 46 TRIP12 is a known E3 ligase of ARF and a regulator of RNF168 with an important role in regulating DDR. 14, [23] [24] [25] By controlling the accumulation of RNF168, TRIP12 prevents excessive spreading of ubiquitinated chromatin at RNF168-damaged chromosomes.
14 However, the mechanisms that regulate TRIP12 were unknown. In the current study, we found that TRIP12 was inversely related to p16 expression and consistent with RNF168-53BP1 and p16-induced DDR changes. Thus we concluded that mechanistically, p16 may affect DDR through the TRIP12-RNF168-53BP1 cascade and that suppression of TRIP12's function is a mechanism underlying p16-mediated radiosensitization (Figure 8 ). In terms of how p16 negatively controls TRIP12 protein levels, our results suggest that p16 may suppress TRIP12 through post-translational modification, although this will require confirmation in future studies. As for how p16 might affect the stability of TRIP12, p16 is not an ubiquitin E3 ligase and thus is unlikely to regulate TRIP12 degradation directly; rather, we believe intervening E3 ligases or deubiquitinases are involved. We are currently in the process of investigating this hypothesis.
p16 was recently found to regulate HR-mediated DDR in vitro by downregulating expression of cyclin D1 protein.
9
E2F1 depletion has also been shown to downregulate cyclin D1 expression. 47 In our study, we found that E2F1 gene expression was downregulated by TRIP12 knockdown (Supplementary  Table S1 ). Colllectively, these results suggest that p16 regulates HR-mediated DDR through p16-TRIP12-RNF168-53BP1 and p16-TRIP12-E2F1-cyclin D1 pathway loops and that TRIP12 is a previously unidentified key mediator of p16's functions in both signaling cascades. TRIP12 has been reported to influence DDR.
14,23-25 However, its role in regulating RT sensitivity has been unclear, and the mechanisms of this effect have not been established. In the current study, knockdown of TRIP12 rendered HNSCC cells sensitive to RT by influencing HR-mediated DDR, suggesting that TRIP12 is a target for RT sensitization.
Finally, we analyzed samples from The Cancer Genome Atlas database and found that high TRIP12 expression was associated with poor outcome in patients with HPV-positive HNSCC. Even though TRIP12 is known to participate in regulating DDR, 14, [23] [24] [25] the relationship of TRIP12 to clinical treatment outcomes had been unknown. Although limited by small numbers of patients, our findings indicate that TRIP12 may be a clinically relevant biomarker of radioresistance in HPV-positive disease and a potential treatment target for overcoming radioresistance.
In conclusion, we confirmed that p16 has a key role in HPV-related favorable treatment outcomes and that TRIP12 mediates p16-related radiation enhancement effects. p16 causes prolonged DDR and leads to RT sensitization. Knockdown of TRIP12 leads to an enhanced response to RT by influencing HR-mediated DDR. High levels of TRIP12 expression are associated with poor outcomes in patients with HPV-positive HNSCC. Because HPV infection is not a feature of most types of cancer, targeting TRIP12 may be a strategy for improving treatment outcomes in such patients. UMSCC-47 and 93-VuSCC-147T cells were maintained in DMEM (Gibco) supplemented with 2% MEM vitamins (Gibco), 1% sodium pyruvate (Lonza, Houston, TX, USA) and 1% non-essential amino acids (Gibco). All media were supplemented with 10% fetal bovine serum (Sigma, St Louis, MO, USA) and 100 U/mL penicillin and 100 μg/mL streptomycin (Gibco).
MATERIALS AND METHODS
Plasmids and shRNA siRNA transfection p16-siRNA (GAUCAUCAGUCACCGAAGG, Thermo Scientific), Trip12-siRNA (GAACACAGAUGGUGCGAUA, Thermo Scientific), RNF168-siRNA (GACA CUUUCUCCACAGAUA, Thermo Scientific) or TP53 (7157)-siRNA (GAAAUU UGCGUGUGGAGUA, Dharmacon) were transfected by electroporation (Nucleofector II, Amaxa, Basel, Switzerland) by using program T-001 with transfection reagent T (Lonza). Cells were collected 48 h later for western blot analysis to validate transfection efficiency. Cells were irradiated 48 h after transfection.
Immunocytochemical analysis
Cells were plated on coverslips that were placed in 35-mm culture dishes. At specified time points after exposure to 4 Gy radiation, cells were fixed in 4% paraformaldehyde for 10 min at ambient temperature, briefly washed in phosphate-buffered saline (Mediatech), and placed in 70% ethanol overnight at 4 1C Fixed cells were permeabilized with 0.1% Igepal for 20 min at ambient temperature, blocked in 2% bovine serum albumin (Sigma) for 1 h, and then incubated in anti-53BP1 (1:200, Cell Signaling) or anti-BRCA1 primary antibody (1:500, Santa Cruz, Dallas, TX, USA) overnight at 4 1C ove Cells were then washed four times with phosphate-buffered saline and then incubated for 1 h in secondary anti-rabbit antibody conjugated to Cy3 (Jackson Immuno Research, West Grove, PA, USA) for 53BP1 foci or in secondary anti-mouse antibody conjugated to FITC or Cy3 (Jackson Immuno Research) to visualize immunoreactivity. DNA was stained with 4 0 ,6-diamidino-2-phenylindole (1:1000, Sigma). Immunoreactions were visualized with a Leica Microsystems microscope (Wetzlar, Germany), and foci were counted manually by using ImageJ software (https://imagej.nih.gov/ij/).
Clonogenic survival assay
Colony-forming ability was assayed as described previously. 31 Briefly, exponentially growing cells were replated in specified numbers into six-well tissue culture dishes for each condition under investigation. Cells were exposed to a single dose of irradiation with a Mark I-68A 137Cs irradiator (JL Shepherd and Associates, San Fernando, CA, USA) with the indicated doses and incubated for 10 days (HN5 and UMSCC-1), 14 days 
Western blot analysis
After irradiation, lysates were obtained at various time points and sonicated (QSonica, Newtown, CT, USA) for 2 min in 0.4 M NaCl/20 mM HEPES buffer containing 1% Igepal, 0.1 mM ethylene glycol tetraacetic acid and ethylenediaminetetraacetic acid, 0.1 M dithiothreitol, 0.1 M phenylmethanesulfonylfluoride, and protease and phosphatase inhibitors (Sigma). Protein concentrations were measured with a DC protein assay kit (Bio-Rad, Hercules, CA, USA). Equalized proteins were subjected to electrophoresis at 60 mA in polyacrylamide pre-cast gels (Bio-Rad) and electrotransferred onto polyvinylidene fluoride membranes (Bio-Rad) at 4°C for 1 h at 100 V. Membranes were blocked with 5% milk (Bio-Rad). Antibodies were incubated overnight in 5% milk at various concentrations (p16, BD Bioscience, San Jose, CA, USA, 1:5000; TRIP12, Santa Cruz, 1:1000; RNF168, Sigma, 1:1000; pRb, CST, 1:500; Rb, CST, 1:1000). Membranes were washed in Tris-buffered saline (Bio-Rad) with 0.1% Tween20 (Sigma) and incubated for 45 min at ambient temperature in 1:2000 antirabbit or anti-mouse IgG (GE Healthcare, Marlborough, MA, USA). Immunoreactions were visualized with the ECL2 system (Thermo Scientific) and then immediately exposed to autoradiographic film (Denville) for various periods. Images were scanned with an HP Scanjet 5550c and quantified with ImageJ software (http://rsbweb.nih.gov/ij/).
Protein half-life detection
The half-life of TRIP12 was tested by using a standard protein synthesis inhibitor cycloheximide assay as previously described. 48 Briefly, control cells or cells overexpressing p16 were treated with 50 μg/mL cycloheximide for the indicated times before lysis, and the expression levels of TRIP12, p16, and glyceraldehyde 3-phosphate dehydrogenase were detected by western blot analysis.
RNA isolation and real-time PCR with reverse transcription
Total RNA was isolated with a mirVana RNA Isolation Kit (Ambion, Foster City, CA, USA) and then reverse-transcribed with an iScript complementary DNA Synthesis Kit (Bio-Rad). The resulting complementary DNA was used for quantitative PCR with TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA, USA), and data were normalized to an endogenous control (glyceraldehyde 3-phosphate dehydrogenase). Real-time PCR and data collection were done with a CFX96 instrument (Bio-Rad).
Tumor radiosensitivity study Animal experiments were done as previously described, 36 in accordance with a protocol approved by the Institutional Animal Care and Use Mice were euthanized when they met the institutional euthanasia criteria for tumor size and overall health condition. Tumors were introduced by intramuscular injection of 1-3 × 10 6 control (mock) or p16-overexpressing HN5 tumor cells or p16-depleted (shp16) or control (scramble) UMSCC-47 tumor cells into the hind legs of 3-to 4-month-old NCR nu/nu mice. Three mutually orthogonal tumor diameters were measured every other day, and mean values were used to quantify tumor regrowth after treatment when tumors reached 8.0 mm (range 7.7-8.2 mm) in diameter. Mice were randomly assigned to groups (using flipping group numbers, e.g., #1 -empty vector no irradiation; #2 -empty vector irradiation; #3 -gene changes no irradiation; #4 -gene changes plus irradiation) without blinding and treated or not treated with fractionated RT. Fractionated radiation (2 Gy per fraction, twice daily for 7 or 5 consecutive days) was delivered to the tumor-bearing limbs of mice by using an irradiator (Co-V, Theratron 780; MDS Nordion, Ottawa, Ontario, Canada) with a cobalt-60 source (field size, 10 × 10 per source axis distance, 64.9rce a at a dose rate of 0.955 Gy/min. During irradiation, unanesthetized mice were mechanically immobilized in a jig so that the tumor was exposed in the radiation field and the animal's body was shielded from radiation exposure.
Clinical data analysis
Samples from patients with HPV-positive HNSCC were identified from The Cancer Genome Atlas HNSCC project by using the cBioPortal for Cancer Genomics. 49, 50 This resource includes data on TRIP12 mRNA expression and survival outcomes for 18 patients with HPV-positive HNSCC.
Statistical analysis
Each experiment was repeated three times or more. Unless otherwise noted, data are presented as mean ± standard error of the mean (s.e.), and Student's t tests (unpaired, unequal variance) were used to compare two groups of independent samples for in vitro radiosensitivity, 53BP1 foci and comet tail moment. Differences in tumor growth delay (Figures 1e and f) were tested with non-parametric bootstrapping of the measured diameters. Delay was estimated as different times to a fixed diameter from linear fits of the two growth curves (Figure 1e : Mock RT vs HN5-p16 RT; Figure 1f : Scramble RT vs sh-p16 RT). Data were confined to times of increasing diameter; these were the times of increasing diameter in Figure 1e , as opposed to all data in Figure 1f . Differences in tumor growth rates ( Figure 1f) were tested by first confirming that the increase in tumor diameter was linear in time (coefficient of t 2 in fit was not significant), then by fitting a linear model that included a parameter that distinguished between the slopes of the two lines. The P value of this parameter was the test of significance of difference in growth rates. For clinical analysis, the upper tertile of TRIP12 expression was used as a cutoff between high and low expression. Group comparisons were done with the Kaplan-Meier method and log-rank tests. Statistical analyses of the clinical data were done with Graph Pad Prism (v6.0), whereas STATA 11 (College Station, TX) was used to analyze animal study data. Po 0.05 was considered statistically significant in all analyses. 
